In 2019, the number of people living with dementia worldwide was enough to fill a small coun...
In 2019, the number of people living with dementia worldwide was enough to fill a small country – 57 million and counting. Fast forward to 2050, and that population is projected to swell to 152 million, a number so vast it could rival the population of Russia! As these numbers grow, so does the urgency for medical breakthroughs that can genuinely alter the course of this ruthless disease.
In the race against time, two recently FDA-approved drugs, Leqembi and Kisunla, have emerged as promising new solutions, each offering a different approach to slowing Alzheimer’s progression. These treatments, though promising, are just the beginning. The ongoing search for complementary therapies that can enhance their overall effects is as crucial as ever.
Enter virtual reality (VR).
Typically associated with gaming and entertainment, VR is now being explored for its potential in Alzheimer’s care. By immersing patients in virtual environments, VR could complement treatments like Leqembi and Kisunla, offering innovative new ways to stimulate memory and enhance cognitive function.
With that in mind, today, we’re exploring how VR could intersect with cutting-edge Alzheimer’s treatments and examining whether the technology can truly transform the future of Alzheimer’s care.
Think of your brain as a vast library, where each memory is a book on a shelf. Over time, the librarian (or the brain) starts misplacing these books, losing track of entire sections. In this instance, Alzheimer’s acts like a thief, sneaking in and scattering these books everywhere, making it harder and harder to find the stories that define a person’s life. But what if there was a way to reorganise the shelves, or at least hold on to the most precious volumes a little longer?
In a world where a person’s surroundings become increasingly unfamiliar, and disorientation and memory loss take hold, it’s believed that VR could offer some sort of safe haven. By immersing patients in familiar and comforting environments, like the streets of their childhood neighbourhood or a beloved holiday destination, VR could rekindle connections to past experiences, reignite neural pathways that have dimmed over time, and enhance cognitive function in ways that traditional therapies might not.
So far, VR has been tested as an early screening tool for Alzheimer’s and to enhance emotional well-being and reduce pain in people living with dementia. These early applications are promising, demonstrating how VR can engage the brain in unique and beneficial ways. For example, instead of simply talking about past experiences, VR programs designed for therapeutic purposes often include tasks that require problem-solving and navigation – activities that help strengthen brain connections. This approach aims to actively engage the cognitive processes that slip away with Alzheimer’s, instead keeping those muscles flexed and ready for action.
Of course, VR isn’t a magic wand that can restore every lost memory, nor is it a replacement for drugs like Leqembi and Kisunla. However, it offers something that’s previously been missing in Alzheimer’s care: a way to connect patients with their pasts in a deeply personal and impactful way. As research continues, VR might just become a valuable supplement to a more comprehensive approach to managing Alzheimer’s.
In the ongoing battle against Alzheimer’s, treatments have often felt like trying to stop a landslide with a shovel. Now, with the arrival of Leqembi and Kinsula, we might finally have tools that are more akin to heavy machinery – powerful and precise in their approach to slowing the disease’s progression.
Leqembi, developed by Eisai and Biogen, zeroes in on amyloid beta – those sticky clumps of protein that build up in the brain and contribute to cognitive decline. By targeting early forms of these troublesome clumps, Leqembi reduces the buildup of amyloid plaques that clog the brain’s communication pathways – a bit like regularly tending to a garden, where consistent care prevents weeds from taking over. By doing so, patients can maintain their cognitive abilities for longer, with study results showing a reduction in cognitive decline by 27% over 18 months and 31% over 36 months, giving patients and their families more time to manage the challenges ahead.
Kisunla, from Eli Lilly, takes a slightly different approach. While it also focuses on reducing amyloid plaques and has been shown to slow cognitive decline by 22% to 35%, Kisunla allows for a more flexible treatment plan. That’s because once a significant amount of plaque has been cleared from the brain, patients can take a break from the medication. This pause in treatment provides a welcome respite from the routine of regular infusions, although it does require careful monitoring through MRI scans due to a higher risk of amyloid-related imaging abnormalities (ARIAs).
Both drugs mark a significant step forward, shifting the focus from just managing symptoms to actively slowing the disease’s progression. While neither drug is a cure, by slowing cognitive decline, they offer patients something incredibly valuable: more time. More time to cherish memories, to continue living their lives, and to spend time with their loved ones.
While we continue looking to these newly approved advancements, it does make us wonder what role VR could play in enhancing cognitive function and quality of life for the millions of people living with Alzheimer’s.
Leqembi and Kisunla have brought us closer to managing Alzheimer’s by slowing its progression. Yet, as promising as these drugs are in reducing cognitive decline, there’s potential to amplify their impact by pairing them with innovative tools like VR.
VR can be used alongside these treatments to create immersive environments that stimulate brain activity in ways that traditional therapies can’t. For instance, while the drugs clear neural pathways, VR can guide patients through virtual landscapes that reinforce memories and boost cognitive function, complementing the medication’s effects.
Let’s take Leqembi, for example. The drug’s mission is to clear out the amyloid plaques that disrupt brain function, but its impact could possibly be amplified with VR. By engaging patients in VR-based cognitive exercises designed to stimulate memory, attention, and problem-solving, VR offers a way to measure and improve cognitive function in real-time. So, as Leqembi works on the biological front, VR could provide immediate feedback, helping patients and caregivers track improvements and fine-tune therapies.
Kisunla, on the other hand, allows for treatment breaks after significant amyloid clearance. The challenge, however, is maintaining cognitive function during these off periods. This is where VR could play a crucial role. By keeping the brain engaged with immersive activities, VR could help sustain the cognitive gains achieved with Kisunla, potentially delaying further decline even when the drug has been paused. Essentially, the technology would act like a bridge, preserving cognitive health while the body takes a breather from the medication.
Combining these cutting-edge drugs with the immersive power of VR would create a multi-dimensional approach to Alzheimer’s care. While the medications work at the biological level, VR would engage the mind in ways that are both therapeutic and deeply human, just like pairing the best training regimen with the perfect diet—each element boosts the other’s effectiveness, offering a more comprehensive path to managing Alzheimer’s.
The potential of VR in Alzheimer’s care is not just about slowing down the disease; it’s about enriching the lives of those affected and making every moment count. While Leqembi and Kisunla represent significant strides in slowing cognitive decline, pairing these drugs with the immersive power of VR could build mental bridges that connect fading memories to the present, enhancing the impact of these treatments.
It’s important, however, not to get ahead of ourselves. VR studies are still in the early experimental phase, and Leqembi and Kisunla have only recently been approved. So, as Alzheimer’s therapies continue to evolve, one thing remains abundantly clear: continued research and clinical trials are essential to unlocking VR's full potential as a complement to these medications.
Overall, we can agree that the future of Alzheimer’s care should be as multifaceted as the disease itself—combining cutting-edge treatments, innovative technologies, and deeply personalised care to improve patient outcomes and drive us closer to finding a long-awaited cure.
After all, in a world where every memory counts, the ability to make those memories last just a little bit longer might be the most powerful promise of all.
For more developments in Alzheimer's care and other neurological advancements, pop over to 5 Groundbreaking Advances in Neurology You Need to Know About.
Is your team working on life-saving innovations that could benefit from specialist expertise? We’re here to help! Whether you need insights and data, top-tier talent, or market strategy, our team of experts can help guide your project toward even greater success. Reach out to us today to find out how we can support your long-term goals.
